Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US38341P1021
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00MVWLLM2
GOSS
Gossamer Bio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Gossamer Bio Inc
ISIN
US38341P1021
TICKER
GOSS
MIC
XNAS
REUTERS
GOSS.OQ
BLOOMBERG
GOSS US
Sun, 26.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 24, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) have opportunity to lead the securities fraud class action lawsuit....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Gossamer Bio
US38341P1021

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026. Gossamer describes itself as a “clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Gossamer Bio
US38341P1021

Notice to Pension Funds, Asset Managers, and FiduciariesNEW YORK, April 23, 2026 /PRNewswire/ -- Institutional investors holding positions in Gossamer Bio, Inc. (NASDAQ: GOSS) during the period between June 16, 2025 and February 20, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutiona...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Gossamer Bio
US38341P1021

Promise vs. Reality: The Gossamer Bio PROSERA Performance GapNEW YORK, April 22, 2026 /PRNewswire/ -- "We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Gossamer Bio
US38341P1021

"We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session. Levi & Korsinsky, LLP notifies investors in Gossamer Bio, Inc. (NASDAQ: GOSS) that a securities cla...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 21.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class period listed are encouraged to c...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 20, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail ar...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Gossamer Bio
US38341P1021

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 16, 2026 /PRNewswire/ -- IMPORTANT DATE: June 1, 2026. Investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your clai...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 15, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS)....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Gossamer Bio
US38341P1021

Notice to Pension Funds, Asset Managers, and FiduciariesNEW YORK, April 15, 2026 /PRNewswire/ -- Institutional investors holding positions in Gossamer Bio, Inc. (NASDAQ: GOSS) during the period between June 16, 2025 and February 20, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutiona...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 14.04.2026       Gossamer Bio
US38341P1021

BENSALEM, Pa., April 14, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTAC...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Gossamer Bio
US38341P1021

PHILADELPHIA, April 13, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the "Class Period")....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 10, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) have opportunity to lead the securities fraud class action lawsuit....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Gossamer Bio
US38341P1021

Lead Plaintiff Deadline June 1, 2026NEW YORK, April 10, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) securities between June 16, 2025 and February 2...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Gossamer Bio
US38341P1021

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Cla...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Gossamer Bio
US38341P1021

Law Offices of Howard G. Smith reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WH...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

"We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session.Levi & Korsinsky, LLP notifies investors in Gossamer Bio, Inc. (NASDAQ: GOSS) that a securities class a...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (th...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class period listed are encouraged to co...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to fil...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to file a lead plaintiff motion.IF...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders wh...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSS...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Law Offices of Howard G. Smith announces an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 3, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GOSS during the cla...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders wh...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

SAN DIEGO, April 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026.  Gossamer is a clinical stage biopharmaceutical company focused on the development and comme...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Gossamer Bio
US38341P1021

The Law Offices of Frank R. Cruz announces an investigation of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSSAMER BIO, INC. (GOSS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink